Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation
The Losartan Intervention For End point reduction in hypertension (LIFE) study
Kristian Wachtell, MD, PhD*, ,*,
Björn Hornestam, MD, PhD ,
Mika Lehto, MD ,
David J. Slotwiner, MD, FACC,
Eva Gerdts, MD, PhD||,
Michael H. Olsen, MD, PhD*,
Peter Aurup, MD¶,
Björn Dahlöf, MD, PhD, FACC,
Hans Ibsen, MD*,
Stevo Julius, MD, FACC#,
Sverre E. Kjeldsen, MD, PhD, FACC**,
Lars H. Lindholm, MD,
Markku S. Nieminen, MD,
Jens Rokkedal, MD* and
Richard B. Devereux, MD, FACC
* Department of Medicine, Glostrup University Hospital, Glostrup, Denmark
Division of Cardiology, Weill Medical College of Cornell University, New York, New York
Department of Medicine, Sahlgrenska University Hospital/Östra, Göteborg, Sweden
Department of Cardiology, Helsinki University Central Hospital, Helsinki, Finland
|| Department of Cardiology, Haukeland University Hospital, Bergen, Norway
¶ Merck Research Laboratories, West Point, Pennsylvania
# Department of Medicine, University of Michigan, Ann Arbor, Michigan
** Department of Preventive Medicine, Umeå University Hospital, Umeå, Sweden
Department of Medicine, Ullevål University Hospital, Oslo, Norway
View larger version (15K):
[in a new window]
|
Figure 1 Systolic, diastolic, and mean arterial blood pressure in hypertensive patients with atrial fibrillation during follow-up; intention-to-treat analysis.
|
|
View larger version (11K):
[in a new window]
|
Figure 2 Heart rate in hypertensive patients with a history of atrial fibrillation treated with losartan and atenolol during follow-up. *p < 0.01. **p < 0.001.
|
|
View larger version (28K):
[in a new window]
|
Figure 3 Kaplan-Meier curves in each treatment group of hypertensive patients with a history of atrial fibrillation for occurrence of (A) the primary composite end point; (B) cardiovascular death; (C) fatal or non-fatal myocardial infarction; (D) fatal or non-fatal stroke; and (E) all-cause mortality.
|
|
|
